[HTML][HTML] The problem of unreasonably high pharmaceutical fees for patients in Chinese hospitals: A system dynamics simulation model
M Li, Y Zhu, C Xue, Y Liu, L Zhang - Computers in Biology and Medicine, 2014 - Elsevier
The social problem of unreasonably high pharmaceutical costs for patients in Chinese
hospitals damages the interests of patients and it has a highly negative impact on the long …
hospitals damages the interests of patients and it has a highly negative impact on the long …
Regulating the relationship between physicians and pharmaceutical companies: a qualitative and descriptive analysis of the impact of Israeli legislation
R Nissanholtz-Gannot, A Yankellevich - Israel Journal of Health Policy …, 2017 - Springer
Abstract Background The Israeli National Health Insurance Law was amended in 2010 to
require the disclosure of payments above 2500 NIS from pharmaceutical companies (PCs) …
require the disclosure of payments above 2500 NIS from pharmaceutical companies (PCs) …
Survey of family doctors' attitudes towards statin treatment in patients with type 2 diabetes
M Hochhauser, O Avoros, V Perman, N Simcha… - Diabetes Research and …, 2019 - Elsevier
Aims Clinical guidelines advocate that cardiovascular benefits of statin treatment overweigh
the risk of impairment of glucose metabolism. The aim of the study was to examine the …
the risk of impairment of glucose metabolism. The aim of the study was to examine the …